Tislelizumab — Drug Intelligence | 32 EU Trials

Filter these 32 trials by condition, phase, country and more.

Open in Search →

32 Registered trials

15 Recruiting

13 Completed trials

22 Sponsors

17 Countries

Phase III

Phase II

Phase I/II

Phase III: 8 Phase II: 17 Phase I/II: 4 Phase I: 1 Phase I (FiH): 2

Oversight events:

4 serious breaches 7 temporary halts 1 unexpected event across 4 trials

View oversight register →

Indications tested

Non-small cell lung cancer 4 Squamous cell carcinoma of head and neck 2 Colorectal cancer 2 Small cell lung cancer extensive stage 1 Adenocarcinoma gastric 1 Renal cell carcinoma 1 Squamous cell carcinoma of the oral cavity 1 Gastrooesophageal cancer 1 Gastric cancer 1 Rectal cancer stage III 1 Soft tissue sarcoma 1 Rectal cancer stage II 1

Sponsors using this IMP

BeOne Medicines AG 4 Novartis Pharma AG 3 Beigene Ltd. 2 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 2 Oncomatryx Biopharma S.A. 2 Oslo University Hospital HF 2 Solti Group 2 University Of Cologne 2 Fondazione GONO G.I. 1 Fondazione GONO Plus 1 Fondazione Italiana Linfomi Onlus 1 Fondazione Ricerca Traslazionale 1

All trials

32 total

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Phase III 9 countries Immunitybio Inc.
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and … Pending

2025-521989-95-00 Phase I/II 1 country Oncomatryx Biopharma S.L.
Rollover study for participants who are currently being treated with and are continuing to benefit from opnurasib as a single agent or in co… Pending

2025-523537-26-00 Phase I/II 5 countries Novartis Pharma AG
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv… Pending

2025-524048-36-00 Phase III 3 countries Fondazione GONO G.I.
A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resec… Recruiting

2024-517565-16-00 Phase II 1 country Fondazione GONO Plus
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting

2024-513185-19-00 Phase I/II 8 countries Novartis Pharma AG
Total Neoadjuvant Treatment with or without Tislelizumab for Locally Advanced Rectal Cancer: An Open-label Randomized Controlled Phase II St… Recruiting

2025-522120-28-00 Phase II 1 country Rabin Medical Center; Universitaetsmedizin der Johannes Gutenberg-Universitaet M…
The purpose of this study is to determine whether Tislelizumab, when given as a subcutaneous (SC) injection, reaches the same drug levels in… Recruiting

2025-522862-58-00 Phase III 6 countries BeOne Medicines AG
FUTURE Recruiting

2024-517573-24-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici… Recruiting

2024-519929-38-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal… Recruiting

2024-518358-17-00 Phase II 1 country University Hospital Of Clermont-Ferrand
PSEUDOVAX – A CANCER VACCINE TARGETING MUTATED GNAS COMBINED WITH IMMUNE CHECKPOINT INHIBITION FOR PATIENTS WITH PSEUDOMYXOMA PERITONEI Recruiting

2024-517047-30-01 Phase I 1 country Oslo University Hospital HF
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib … Recruiting

2025-520743-33-00 Phase I/II 1 country Oncomatryx Biopharma S.A.
Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) Recruiting

2024-519205-35-01 Phase II 1 country Fondazione Ricerca Traslazionale
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting

2024-513779-42-02 Phase II 1 country Oslo University Hospital HF
tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting

2023-503316-33-00 Phase III 1 country Institut Gustave Roussy
Phase II study: efficacy and safety of tislelizumab in patients with de novo Hodgkin lymphoma unsuitable for standard chemotherapy Recruiting

2022-503090-11-00 Phase II 1 country Fondazione Italiana Linfomi Onlus
Testing immunotherapy for patients with liver cancer and moderatelyaltered liver functions Recruiting

2024-516443-57-00 Phase II 1 country Unicancer
A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS… Recruiting

2023-504653-12-00 Phase II 3 countries University Of Cologne
Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended

2023-508073-87-00 Phase I (FiH) 7 countries Novartis Pharma AG
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Phase II 1 country University Of Cologne
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer. Ended

2022-502738-18-00 Phase II 4 countries BeOne Medicines AG
HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation… Ended

2022-502225-17-00 Phase II 3 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas… Ended

2023-510319-20-00 Phase III 12 countries Jazz Pharmaceuticals Ireland Limited

Showing 1–24 of 32 trials

← All drugs A–Z